BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 33002954)

  • 1. Treatment of coronavirus disease 2019.
    Hung IFN
    Curr Opin HIV AIDS; 2020 Nov; 15(6):336-340. PubMed ID: 33002954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential strategies for combating COVID-19.
    Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
    Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How likely are COVID-19 interventions to benefit the sickest patients?
    Perner A; Tirupakuzhi Vijayaraghavan BK; Venkatesh B
    Intensive Care Med; 2020 Jul; 46(7):1441-1444. PubMed ID: 32519004
    [No Abstract]   [Full Text] [Related]  

  • 7. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments.
    Goodarzi P; Mahdavi F; Mirzaei R; Hasanvand H; Sholeh M; Zamani F; Sohrabi M; Tabibzadeh A; Jeda AS; Niya MHK; Keyvani H; Karampoor S
    Int Immunopharmacol; 2020 Nov; 88():106885. PubMed ID: 32795893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic approaches to curtail COVID-19.
    Owji H; Negahdaripour M; Hajighahramani N
    Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
    Schijns V; Lavelle EC
    Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for caring for patients with severe and nonsevere COVID-19.
    Paladugu S; Donato AA
    Ann Intern Med; 2020 Jul; 173(2):JC3. PubMed ID: 32687760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
    Subramanian K; Nalli A; Senthil V; Jain S; Nayak A; Bhat A
    Adv Ther; 2020 Oct; 37(10):4107-4131. PubMed ID: 32809210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential pharmacological agents for COVID-19.
    Kotwani A; Gandra S
    Indian J Public Health; 2020 Jun; 64(Supplement):S112-S116. PubMed ID: 32496239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
    Barlow A; Landolf KM; Barlow B; Yeung SYA; Heavner JJ; Claassen CW; Heavner MS
    Pharmacotherapy; 2020 May; 40(5):416-437. PubMed ID: 32259313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of SARS-CoV-2: How far have we reached?
    Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
    Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Audio Interview: Capitalizing on Immune Responses to Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: Information on the COVID-19 Pandemic continued.
    Rock G
    Transfus Apher Sci; 2020 Aug; 59(4):102854. PubMed ID: 32660893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.